Human Papillomavirus-Related Non-Metastatic Oropharyngeal
Carcinoma: Current Local Treatment Options and Future
Perspectives

J 2022

Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives

ŠVAJDOVÁ, Michaela; Pavol DUBINSKÝ; Tomáš KAZDA a Branislav JEREMIC

Základní údaje

Originální název

Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives

Název česky

Nemetastatický karcinom orofaryngu asociovaný s infekcí lidským papilomavirem: současné lokální možnosti terapie a budoucí perspektivy

Autoři

ŠVAJDOVÁ, Michaela; Pavol DUBINSKÝ; Tomáš KAZDA a Branislav JEREMIC

Vydání

Cancers, Basel, MDPI, 2022, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.200

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/22:00127071

Organizační jednotka

Lékařská fakulta

Klíčová slova česky

karcinom orofaryngu, lidský papilomavirus, deintenzifikace, minimálně invazívní chirurgie, radioterapie, systémová léčba, deeskalace, kvalita života

Klíčová slova anglicky

oropharyngeal cancer; human papillomavirus; deintensification; minimally-invasive surgery; radiation therapy; systemic therapy; de-escalation; quality of life

Štítky

14110812, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 1. 2023 14:55, Mgr. Tereza Miškechová

Anotace

V originále

Simple Summary Current options for the curative treatment of the non-metastatic oropharyngeal carcinoma associated with human papillomavirus include minimally-invasive surgery or radiotherapy, which is combined with chemotherapy in many clinical situations. The aim of this review is to summarize the current treatment recommendations in the local therapy of human papillomavirus-associated oropharyngeal cancer, with respect to the latest published evidence in the field. Future perspectives and next-generation research pathways, including treatment deintensification methods, are thoroughly discussed. Over the last two decades, human papillomavirus (HPV) has caused a new pandemic of cancer in many urban areas across the world. The new entity, HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), has been at the center of scientific attention ever since, not only due to its distinct biological behavior, but also because of its significantly better prognosis than observed in its HPV-negative counterpart. The very good treatment outcomes of the disease after primary therapy (minimally-invasive surgery, radiation therapy with or without chemotherapy) resulted in the creation of a separate staging system, reflecting this excellent prognosis. A substantial proportion of newly diagnosed HPV-driven OPSCC is diagnosed in stage I or II, where long-term survival is observed worldwide. Deintensification of the primary therapeutic methods, aiming at a reduction of long-term toxicity in survivors, has emerged, and the quality of life of the patient after treatment has become a key-point in many clinical trials. Current treatment recommendations for the treatment of HPV-driven OPSCC do not differ significantly from HPV-negative OPSCC; however, the results of randomized trials are eagerly awaited and deemed necessary, in order to include deintensification into standard clinical practice.

Přiložené soubory

cancers-14-05385.pdf Verze souboru

Citovat

ŠVAJDOVÁ, Michaela; Pavol DUBINSKÝ; Tomáš KAZDA a Branislav JEREMIC. Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives. Cancers. Basel: MDPI, 2022, roč. 14, č. 21, s. 1-26. ISSN 2072-6694. Dostupné z: https://doi.org/10.3390/cancers14215385.

@article{2228757,
   author = {Švajdová, Michaela and Dubinský, Pavol and Kazda, Tomáš and Jeremic, Branislav},
   article_location = {Basel},
   article_number = {21},
   doi = {https://doi.org/10.3390/cancers14215385},
   keywords = {oropharyngeal cancer; human papillomavirus; deintensification; minimally-invasive surgery; radiation therapy; systemic therapy; de-escalation; quality of life},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives},
   url = {https://www.mdpi.com/2072-6694/14/21/5385},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 2228757
AU  - Švajdová, Michaela - Dubinský, Pavol - Kazda, Tomáš - Jeremic, Branislav
PY  - 2022
TI  - Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives
JF  - Cancers
VL  - 14
IS  - 21
SP  - 1-26
EP  - 1-26
PB  - MDPI
SN  - 20726694
KW  - oropharyngeal cancer
KW  - human papillomavirus
KW  - deintensification
KW  - minimally-invasive surgery
KW  - radiation therapy
KW  - systemic therapy
KW  - de-escalation
KW  - quality of life
UR  - https://www.mdpi.com/2072-6694/14/21/5385
N2  - Simple Summary Current options for the curative treatment of the non-metastatic oropharyngeal carcinoma associated with human papillomavirus include minimally-invasive surgery or radiotherapy, which is combined with chemotherapy in many clinical situations. The aim of this review is to summarize the current treatment recommendations in the local therapy of human papillomavirus-associated oropharyngeal cancer, with respect to the latest published evidence in the field. Future perspectives and next-generation research pathways, including treatment deintensification methods, are thoroughly discussed. Over the last two decades, human papillomavirus (HPV) has caused a new pandemic of cancer in many urban areas across the world. The new entity, HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), has been at the center of scientific attention ever since, not only due to its distinct biological behavior, but also because of its significantly better prognosis than observed in its HPV-negative counterpart. The very good treatment outcomes of the disease after primary therapy (minimally-invasive surgery, radiation therapy with or without chemotherapy) resulted in the creation of a separate staging system, reflecting this excellent prognosis. A substantial proportion of newly diagnosed HPV-driven OPSCC is diagnosed in stage I or II, where long-term survival is observed worldwide. Deintensification of the primary therapeutic methods, aiming at a reduction of long-term toxicity in survivors, has emerged, and the quality of life of the patient after treatment has become a key-point in many clinical trials. Current treatment recommendations for the treatment of HPV-driven OPSCC do not differ significantly from HPV-negative OPSCC; however, the results of randomized trials are eagerly awaited and deemed necessary, in order to include deintensification into standard clinical practice.
ER  -

ŠVAJDOVÁ, Michaela; Pavol DUBINSKÝ; Tomáš KAZDA a Branislav JEREMIC. Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives. \textit{Cancers}. Basel: MDPI, 2022, roč.~14, č.~21, s.~1-26. ISSN~2072-6694. Dostupné z: https://doi.org/10.3390/cancers14215385.

Přehled o publikaci